牛牛AI助理已提取核心訊息
On March 1, 2024, Shattuck Labs, Inc., a clinical-stage biotechnology company, announced the expansion of its Board of Directors with the appointment of Dr. Clay Siegall and Dr. Kate Sasser, effective immediately. Dr. Siegall, with a notable background as President, CEO, and Chairman of Immunome, Inc., brings extensive experience in drug development and pharmaceutical leadership. Dr. Sasser, currently the Chief Scientific Officer at Tempus AI, has a strong track record in translational research and precision medicine. Both appointees are expected to receive compensation in line with the company's non-employee director policy and will enter into the company's standard indemnification agreement. The appointments come at a strategic time as Shattuck Labs prepares for significant clinical updates and potential expansion of pivotal studies for its lead program SL-172154, which is currently in multiple Phase 1 trials. The company, which specializes in developing bifunctional fusion proteins for cancer and autoimmune disease treatment, anticipates these appointments will contribute to its transition to late-stage clinical development and support its growth objectives.
On March 1, 2024, Shattuck Labs, Inc., a clinical-stage biotechnology company, announced the expansion of its Board of Directors with the appointment of Dr. Clay Siegall and Dr. Kate Sasser, effective immediately. Dr. Siegall, with a notable background as President, CEO, and Chairman of Immunome, Inc., brings extensive experience in drug development and pharmaceutical leadership. Dr. Sasser, currently the Chief Scientific Officer at Tempus AI, has a strong track record in translational research and precision medicine. Both appointees are expected to receive compensation in line with the company's non-employee director policy and will enter into the company's standard indemnification agreement. The appointments come at a strategic time as Shattuck Labs prepares for significant clinical updates and potential expansion of pivotal studies for its lead program SL-172154, which is currently in multiple Phase 1 trials. The company, which specializes in developing bifunctional fusion proteins for cancer and autoimmune disease treatment, anticipates these appointments will contribute to its transition to late-stage clinical development and support its growth objectives.
2024 年 3 月 1 日，臨床階段的生物技術公司 Shattuck Labs, Inc. 宣佈擴大其董事會，任命克萊·西格爾博士和凱特·薩瑟博士，立即生效。西格爾博士擁有Immunome, Inc. 總裁、首席執行官和董事長的豐富背景，在藥物開發和製藥領導方面擁有豐富的經驗。薩瑟博士現任Tempus AI首席科學官，在轉化研究和精準醫療方面有着良好的記錄。預計兩名被任命者都將獲得符合公司非僱員董事政策的薪酬，並將簽訂公司的標準賠償協議。這些任命是在一個戰略時刻作出的，因爲Shattuck Labs正在爲其主要項目 SL-172154 的重大臨床更新和關鍵研究的潛在擴展做準備，該項目目前正在進行多項1期試驗。該公司專門開發用於癌症和自身免疫性疾病治療的雙功能融合蛋白，預計這些任命將有助於其過渡到後期臨床開發並支持其增長目標。
2024 年 3 月 1 日，臨床階段的生物技術公司 Shattuck Labs, Inc. 宣佈擴大其董事會，任命克萊·西格爾博士和凱特·薩瑟博士，立即生效。西格爾博士擁有Immunome, Inc. 總裁、首席執行官和董事長的豐富背景，在藥物開發和製藥領導方面擁有豐富的經驗。薩瑟博士現任Tempus AI首席科學官，在轉化研究和精準醫療方面有着良好的記錄。預計兩名被任命者都將獲得符合公司非僱員董事政策的薪酬，並將簽訂公司的標準賠償協議。這些任命是在一個戰略時刻作出的，因爲Shattuck Labs正在爲其主要項目 SL-172154 的重大臨床更新和關鍵研究的潛在擴展做準備，該項目目前正在進行多項1期試驗。該公司專門開發用於癌症和自身免疫性疾病治療的雙功能融合蛋白，預計這些任命將有助於其過渡到後期臨床開發並支持其增長目標。
有用
沒用